

Bavarian Nordic Announces Major Shareholder Notification from Johnson & Johnson Innovation – JJDC, Inc.

Copenhagen, Denmark, March 30, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today, as set out in Section 38 in the Danish Capital Markets Act, received the following major shareholder notification resulting from the increase in the Company's share capital, registered today with the Danish Business Authority:

Johnson & Johnson Innovation – JJDC, Inc. has made a notification that as per March 30, 2020 they continue to hold 1,844,086 shares, which now corresponds to 3.16% of the share capital and voting rights in the Company.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts

Thomas Duschek
Investor Relations & Communications (EU)
Tel: +45 30 66 35 99

Graham Morrell, Paddock Circle Advisors (US)
graham@paddockcircle.com
Tel: +1 781 686 9600

Company Announcement no. 18 / 2020

Attachment

| [2020-18-en](#)

Bavarian Nordic A/S offentliggør storaktionærmeddelelse fra Johnson & Johnson Innovation – JJDC, Inc.

KØBENHAVN, Danmark, 30. marts 2020 – Bavarian Nordic A/S (OMX: BAVA) har i henhold til §38 i lov om kapitalmarkeder modtaget følgende storaktionærmeddelelse, som følge af forhøjelsen af selskabets aktiekapital, der i dag er registreret hos Erhvervsstyrelsen.

Johnson & Johnson Innovation – JJDC, Inc har meddelt, at de pr. 30. marts 2020 fortsat ejer 1.844.086 aktier i selskabet, hvilket nu svarer til 3,16% af aktiekapitalen og stemmerettighederne i selskabet.

Om Bavarian Nordic

Bavarian Nordic er et fuldt integreret biotekselskab, der er fokuseret på udvikling, produktion og kommercialisering af livsvigtige vacciner. Vi er globalt førende inden for koppevacciner, og er mangeårig leverandør til det amerikanske strategiske nationale beredskabslager af en ikke-replikerende koppevaccine, som er godkendt af de amerikanske sundhedsmyndigheder, også til beskyttelse mod abekopper. Vores kommercielle produktportefølje består endvidere af markedsledende vacciner mod rabies og flåtbåren hjernebetændelse. Med udgangspunkt i vores virale vaccineplatform, MVA-BN®, har vi udviklet en bred portefølje af produktkandidater, der sigter mod at forbedre og beskytte liv ved at frigøre immunsystemets egne kræfter. Blandt andet har vi udviklet en ebolavaccine, der er licenseret til Janssen. For yderligere information besøg www.bavarian-nordic.com.

Kontakt

Thomas Duschek
Investor Relations & Communications
Tel: +45 30 66 35 99

Vedhæftet fil

| [2020-18-da](#)